HX-1171 | HTHQ | CAS#148081-72-5 | Lipid Peroxidation Inhibitor

MedKoo Cat#: 527702 | Name: HX-1171

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HX-1171, also known as HTHQ, is a lipid peroxidation inhibitor potentially for the treatment of hepatic fibrosis. HTHQ and vitamin E attenuated interleukin-1beta-induced iNOS protein expression in cultured hepatocytes, the potency of HTHQ being 10-times higher than that of vitamin E. HTHQ may prevent tumor production induced by AP and NaNO2 more effectively than ascorbic acid.

Chemical Structure

HX-1171

CAS#148081-72-5

Theoretical Analysis

MedKoo Cat#: 527702

Name: HX-1171

CAS#: 148081-72-5

Chemical Formula: C15H24O2

Exact Mass: 236.1776

Molecular Weight: 236.36

Elemental Analysis: C, 76.23; H, 10.24; O, 13.54

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 280.00	2 Weeks
100mg	USD 520.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

HX-1171; HX-1171; HX-1171; HTHQ

IUPAC/Chemical Name

4-(hexyloxy)-2,3,6-trimethylphenol

InChi Key

ATMNQRRJNBCQJO-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H24O2/c1-5-6-7-8-9-17-14-10-11(2)15(16)13(4)12(14)3/h10,16H,5-9H2,1-4H3

SMILES Code

OC1=C(C)C=C(OCCCCCC)C(C)=C1C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 236.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kim YH, Choi HY, Lee SH, Lim HS, Miki T, Kang JK, Han KG, Bae KS. Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers. Drug Des Devel Ther. 2015 Mar 23;9:1735-42. doi: 10.2147/DDDT.S79724. PubMed PMID: 25848210; PubMed Central PMCID: PMC4376184. 2: Jung YR, Lee YJ, Lee NJ, Lin CM, Moon JH, Chai HY, Kang JK. Inhibitory Effect of 1-O-Hexyl-2,3,5-Trimethylhydroquinone on Dimethylnitrosamine-induced Liver Fibrosis in Male SD Rats. Toxicol Res. 2010 Sep;26(3):193-201. doi: 10.5487/TR.2010.26.3.193. PubMed PMID: 24278524; PubMed Central PMCID: PMC3834479. 3: An J, Feng GG, Huang L, Kurokawa T, Nonami T, Koide T, Kondo F, Komatsu T, Tsunekawa K, Fujiwara Y, Goto H, Nishikawa H, Miki T, Sugiyama S, Ishikawa N. Effects of 1-O-hexyl-2,3,5-trimethylhydroquinone on carbon tetrachloride-induced hepatic cirrhosis in rats. Hepatol Res. 2010 Jun;40(6):613-21. doi: 10.1111/j.1872-034X.2010.00638.x. PubMed PMID: 20412328. 4: Yada H, Hirose M, Tamano S, Kawabe M, Sano M, Takahashi S, Futakuchi M, Miki T, Shirai T. Effects of antioxidant 1-O-hexyl-2,3,5-trimethylhydroquinone or ascorbic acid on carcinogenesis induced by administration of aminopyrine and sodium nitrite in a rat multi-organ carcinogenesis model. Jpn J Cancer Res. 2002 Dec;93(12):1299-307. PubMed PMID: 12495469. 5: Liu W, Itoigawa M, Miki T, Nishikawa H, Sugiyama S, Ishikawa N. 1-O-hexyl-2,3,5-trimethylhydroquinone inhibits IkappaB phosphorylation and degradation-linked inducible nitric oxide synthase expression: beyond antioxidant function. J Pharm Pharmacol. 2002 Mar;54(3):383-9. PubMed PMID: 11902804. 6: Futakuchi M, Hirose M, Imaida K, Takahashi S, Ogawa K, Asamoto M, Miki T, Shirai T. Chemoprevention of 2-amino-1-methyl-6-phenylimidazo- [4,5-b]pyridine-induced colon carcinogenesis by 1-O-hexyl-2,3,5-trimethylhydroquinone after initiation with 1,2-dimethylhydrazine in F344 rats. Carcinogenesis. 2002 Feb;23(2):283-7. PubMed PMID: 11872633. 7: Hino T, Kawanishi S, Yasui H, Oka S, Sakurai H. HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone), an anti-lipid-peroxidative compound: its chemical and biochemical characterizations. Biochim Biophys Acta. 1998 Sep 16;1425(1):47-60. PubMed PMID: 9813237. 8: Ogawa K, Futakuchi M, Hirose M, Boonyaphiphat P, Mizoguchi Y, Miki T, Shirai T. Stage and organ dependent effects of 1-O-hexyl-2,3,5-trimethylhydroquinone, ascorbic acid derivatives, n-heptadecane-8-10-dione and phenylethyl isothiocyanate in a rat multiorgan carcinogenesis model. Int J Cancer. 1998 Jun 10;76(6):851-6. PubMed PMID: 9626352. 9: Futakuchi M, Hirose M, Miki T, Tanaka H, Ozaki M, Shirai T. Inhibition of DMBA-initiated rat mammary tumour development by 1-O-hexyl-2,3,5-trimethylhydroquinone, phenylethyl isothiocyanate, and novel synthetic ascorbic acid derivatives. Eur J Cancer Prev. 1998 Apr;7(2):153-9. PubMed PMID: 9818778. 10: Mizoguchi Y, Hirose M, Yamaguchi T, Boonyaphiphat P, Miki T, Shirai T. Dose dependence of 1-O-hexyl-2,3,5-trimethylhydroquinone promotion of forestomach carcinogenesis in rats pretreated with N-ethylnitrosourethane. Jpn J Cancer Res. 1998 May;89(5):475-80. PubMed PMID: 9685849. 11: Hirose M, Hasegawa R, Kimura J, Akagi K, Yoshida Y, Tanaka H, Miki T, Satoh T, Wakabayashi K, Ito N, et al. Inhibitory effects of 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), green tea catechins and other antioxidants on 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1)-induced rat hepatocarcinogenesis and dose-dependent inhibition by HTHQ of lesion induction by Glu-P-1 or 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). Carcinogenesis. 1995 Dec;16(12):3049-55. PubMed PMID: 8603484. 12: Hirose M, Iwata S, Ito E, Nihro Y, Takahashi S, Mizoguchi Y, Miki T, Satoh T, Ito N, Shirai T. Strong anti-mutagenic activity of the novel lipophilic antioxidant 1-O-hexyl-2,3,5-trimethylhydroquinone against heterocyclic amine-induced mutagenesis in the Ames assay and its effect on metabolic activation of 2-amino-6-methyldipyrido[1,2-a:3',2'-d] imidazole (Glu-p-1). Carcinogenesis. 1995 Sep;16(9):2227-32. PubMed PMID: 7554080. 13: Hirose M, Akagi K, Hasegawa R, Satoh T, Nihro Y, Miki T, Sugimura T, Ito N. Strong inhibition of 2-amino-6-methyldipyrido[1,2-a:3',2'-d] imidazole-induced mutagenesis and hepatocarcinogenesis by 1-O-hexyl-2,3,5-trimethylhydroquinone. Jpn J Cancer Res. 1993 May;84(5):481-4. PubMed PMID: 8320163. 14: Hirose M, Takahashi S, Ogawa K, Futakuchi M, Shirai T. Phenolics: blocking agents for heterocyclic amine-induced carcinogenesis. Food Chem Toxicol. 1999 Sep-Oct;37(9-10):985-92. PubMed PMID: 10541455. 15: Hirose M, Futakuchi M, Tanaka H, Orita SI, Ito T, Miki T, Shirai T. Prevention by antioxidants of heterocyclic amine-induced carcinogenesis in a rat medium-term liver bioassay: results of extended and combination treatment experiments. Eur J Cancer Prev. 1998 Feb;7(1):61-7. PubMed PMID: 9511852. 16: Lee KY, Shibutani M, Kuroiwa K, Takagi H, Inoue K, Nishikawa H, Miki T, Hirose M. Chemoprevention of acrylamide toxicity by antioxidative agents in rats--effective suppression of testicular toxicity by phenylethyl isothiocyanate. Arch Toxicol. 2005 Sep;79(9):531-41. PubMed PMID: 15864552. 17: Ito N, Hasegawa R, Imaida K, Tamano S, Hagiwara A, Hirose M, Shirai T. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat. Mutat Res. 1997 May 12;376(1-2):107-14. PubMed PMID: 9202745. 18: Hirose M, Nishikawa A, Shibutani M, Imai T, Shirai T. Chemoprevention of heterocyclic amine-induced mammary carcinogenesis in rats. Environ Mol Mutagen. 2002;39(2-3):271-8. PubMed PMID: 11921198. 19: Hirose M, Takahashi S, Ogawa K, Futakuchi M, Shirai T, Shibutani M, Uneyama C, Toyoda K, Iwata H. Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats. Cancer Lett. 1999 Sep 1;143(2):173-8. PubMed PMID: 10503899. 20: Hirose M, Ito T, Takahashi S, Ozaki M, Ogiso T, Nihro Y, Miki T, Shirai T. Prevention by synthetic phenolic antioxidants of 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)- or activated MeIQx-induced mutagenesis and MeIQx-induced rat hepatocarcinogenesis, and role of antioxidant activity in the prevention of carcinogenesis. Eur J Cancer Prev. 1998 Jun;7(3):233-41. PubMed PMID: 9696932.